Key facts
- This page summarizes Huda Y. Zoghbi's Form 4 filing for REGENERON PHARMACEUTICALS, INC. (REGN).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 05 Nov 2026, 16:05.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Sale
Sale
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Additional SEC filing notes
Footnote F1
Represents volume-weighted average price of sales of 6,939 shares of Company stock on November 3, 2026 at prices ranging from $970.00 to $970.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 3, 2026 at each separate price.
Footnote F2
Represents volume-weighted average price of sales of 500 shares of Company stock on November 3, 2026 at prices ranging from $971.00 to $971.11. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 3, 2026 at each separate price.
Footnote F3
The stock option vested in three equal annual installments, commencing one year after the date of grant.